Literature DB >> 10683301

Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin.

A M Humm1, C Pabst, T Lauterburg, J M Burgunder.   

Abstract

Botulinum toxin is used to induce transient graded paresis by chemodenervation in the treatment of focal hyperkinetic movement disorders. While the molecular events occurring in motoneurons after mechanical nerve lesioning leading to muscle paresis are well known, they have been investigated to a lesser extent after chemodenervation. We therefore examined the expression of enkephalin (ENK), acidic fibroblast growth factor (aFGF), neurotensin (NT), galanin (GAL), substance P (SP), vasoactive intestinal polypeptide (VIP), and neuropeptide Y (NPY) in rat spinal motoneurons after chemodenervation of the gastrocnemius. In order to precisely localize the motoneurons targeting the injection site, retrograde tracing was performed in additional rats by using Fluorogold injections. ENK expression was upregulated in the region corresponding to the Fluorogold positive motoneurons, but also on the contralateral side and in more distant parts of the spinal cord. The highest upregulation occurred 7 to 14 days after injections and decreased over a period of three months. At 8 days, aFGF was slightly downregulated in all regions studied, single motoneurons showed NT expression, while expression of GAL, SP, VIP, and NPY could be detected neither in controls nor in toxin-treated animals. These alterations in gene expression were strikingly different from those described after axotomy. Our present findings give additional demonstration of the considerable plasticity of the adult spinal cord after botulinum toxin treatment. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683301     DOI: 10.1006/exnr.1999.7268

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study.

Authors:  Larissa Bittencourt da Silva; Ali Karshenas; Flemming Winther Bach; Sten Rasmussen; Lars Arendt-Nielsen; Parisa Gazerani
Journal:  Pain Res Manag       Date:  2014 May-Jun       Impact factor: 3.037

Review 2.  Botulinum toxin for the treatment of musculoskeletal pain and spasm.

Authors:  Geoffrey Sheean
Journal:  Curr Pain Headache Rep       Date:  2002-12

Review 3.  Botulinum toxin type A in motor nervous system: unexplained observations and new challenges.

Authors:  I Matak; Z Lacković; M Relja
Journal:  J Neural Transm (Vienna)       Date:  2016-09-01       Impact factor: 3.575

Review 4.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

5.  Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action.

Authors:  Uwe Wollina
Journal:  J Cutan Aesthet Surg       Date:  2008-01

Review 6.  Preventative treatment for migraine and tension-type headaches : do drugs having effects on muscle spasm and tone have a role?

Authors:  Frederick G Freitag
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 7.  Botulinum Toxin in the Field of Dermatology: Novel Indications.

Authors:  Yoon Seob Kim; Eun Sun Hong; Hei Sung Kim
Journal:  Toxins (Basel)       Date:  2017-12-16       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.